Literature DB >> 16701148

IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.

Louisa K Wilcock1, James N Francis, Stephen R Durham.   

Abstract

IgE-facilitated allergen presentation (FAP) is an important pathogenic mechanism in allergic disease and represents a potential therapeutic target. Allergen immunotherapy is a highly effective therapy, particularly in patients with seasonal pollinosis who fail to respond to usual pharmacotherapy. Allergen immunotherapy induces "blocking" IgG antibodies that are detectable in serum and have been shown to inhibit IgE-FAP in vitro. This review summarizes the main components involved in IgE-FAP and the potential value of a validated functional assay of serum inhibitory antibodies for IgE-FAP for monitoring the clinical response to immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16701148     DOI： 10.1016/j.iac.2006.02.004

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  14 in total

1.  An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.

Authors:  Areeg H El-Gharbawy; Joanne Mackey; Stephanie DeArmey; Greg Westby; Sherry G Grinnell; Peggy Malovrh; Robert Conway; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-07-13       Impact factor: 4.797

2.  Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments.

Authors:  Pauline N M Mwinzi; Lisa Ganley-Leal; Carla L Black; W Evan Secor; Diana M S Karanja; Daniel G Colley
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

3.  Clinical efficacy and immune regulation with peanut oral immunotherapy.

Authors:  Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-07-03       Impact factor: 10.793

Review 4.  New roles for mast cells in modulating allergic reactions and immunity against pathogens.

Authors:  Alison M Hofmann; Soman N Abraham
Journal:  Curr Opin Immunol       Date:  2009-10-12       Impact factor: 7.486

5.  A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.

Authors:  Robert A Wood; Jennifer S Kim; Robert Lindblad; Kari Nadeau; Alice K Henning; Peter Dawson; Marshall Plaut; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2015-11-12       Impact factor: 10.793

6.  Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.

Authors:  Andrew C Nyborg; Anna Zacco; Rachel Ettinger; M Jack Borrok; Jie Zhu; Tom Martin; Rob Woods; Christine Kiefer; Michael A Bowen; E Suzanne Cohen; Ronald Herbst; Herren Wu; Steven Coats
Journal:  Cell Mol Immunol       Date:  2015-03-23       Impact factor: 11.530

Review 7.  Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions.

Authors:  Louisa K James; Stephen J Till
Journal:  Curr Allergy Asthma Rep       Date:  2016-03       Impact factor: 4.806

8.  Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction.

Authors:  Frederic Jabs; Melanie Plum; Nick S Laursen; Rasmus K Jensen; Brian Mølgaard; Michaela Miehe; Marco Mandolesi; Michèle M Rauber; Wolfgang Pfützner; Thilo Jakob; Christian Möbs; Gregers R Andersen; Edzard Spillner
Journal:  Nat Commun       Date:  2018-01-02       Impact factor: 14.919

Review 9.  Tracing IgE-Producing Cells in Allergic Patients.

Authors:  Julia Eckl-Dorna; Sergio Villazala-Merino; Nicholas James Campion; Maria Byazrova; Alexander Filatov; Dmitry Kudlay; Antonina Karsonova; Ksenja Riabova; Musa Khaitov; Alexander Karaulov; Verena Niederberger-Leppin; Rudolf Valenta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

10.  A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

Authors:  E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May
Journal:  MAbs       Date:  2014-02-28       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.